Winner of
Computerworld Honors 2009
A European multidisciplinary network for the fight against HIV drug resistance
The EuResist Integrated Database
with data of more than 105.000 HIV patients is open for research studies.
The EuResist Network shines at the Nordic HIV & Virology Conference 2024.
Prof. Anders Sönnerborg moderated the plenary session: “HIV Persistence and Cure”. Dr. Rolf Kaiser and Dr. Martin Pirkl shared insights on "Resistance Test Tools and Their Application in Clinical Routine" during the plenary session on Antiviral Treatment and Resistance".
Prof. Milosz Parcewski presented "Phylogenetic Evolution and Spread of HIV-1 Subtype A6 from Ukraine" during the plenary session on Epidemiology.
The Nordic HIV & Virology Conference represents a great opportunity for discussing science in a very stimulating environment.
EuResist Network shines at Nordic HIV & Virology Conference 2024
25-27 September 2024
A new article about the EuCARE schools study was just published online by the national Italian newspaper "Il fatto quotidiano".
Sara Gandini (from the European Institute of Oncology) and Francesca Incardona (EuCARE project coordinator), discuss the study's findings on the effects of distance learning on students.
The preliminary results of the EuCARE research suggest that students experienced higher anxiety, stress, and loneliness during remote learning.
This initial findings were presented at the ICAR (International Conference on Antiviral Research) in Rome in June 2024 .
EuCARE article on the distance learning and the impact on students grades and confidence
9 July 2024
EuResist at “La sanità che vorrei”, Italian Ministry of Health
3 July 2024
Francesca Incardona, participated in the high level institutional event on “The healthcare I wish (La sanità che vorrei)”, organized by the Italian Society for Infectious and Tropical Diseases (SIMIT).
The event is hosted by the Italian Ministry of Health in Rome on July 3 from 10:30 to 13:00 and discussed the clinical and social aspects of health education and awareness of behaviours.
Key public policy stakeholders and scientists participated in the meeting.
The EuCARE session at ICAR 2024
20 June 2024
EuCARE presented its most recent scientific results in a dedicated session at the ICAR 2024 conference in Rome.
The session, chaired by Giulia Carla Marchetti and Francesca Ceccherini Silberstein, featured 7 presentations from EuCARE project partners, including Maurizio Zazzi, Sara Gandini, Francesca Incardona, Elham Shamshara, Alessandro Cozzi-Lepri, Roberta Rovito e Andrea Santoro.
The EuCARE session prompted a lively discussion with the audience in an interesting, useful Q&A session as in the spirit of ICAR.
The ICAR conference is the major Italian event in the field of HIV/AIDS research, now at its 16th edition.
New EuResist paper on Bioinformatics
22 May 2024
A key question in predicting HIV therapy outcomes is whether incorporating historical information can improve predictions compared to relying solely on current or most recent data.
The paper, titled “Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1”, investigates if including past knowledge – specifically viral mutations from all pre-therapy genotypic tests, their order of detection and corresponding viral load measurements – can enhance the accuracy of predicting treatment success.
The study, led by Giulia Di Teodoro, leveraged the EuResist Integrated DataBase (EIDB). For enhanced replicability, we encourage reproducing this study with the latest EIDB release. Access is available upon contacting the EuResist Network.
EuCARE data at ICAR 2024
20 June 2024
We are delighted and honoured to have a symposium dedicated to the EuCARE project during ICAR 2024, the Italian Conference on Aids and Antiviral Research taking place in Rome from 19 to 21 June 2024.
SARS-COV-2 and its continuous evolution still pose scientific questions and challenges, including those related to its immune pathogenesis and to long-COVID. The pandemic also highlighted the need for research on areas like vaccine hesitancy and non-pharmacological interventions, e.g. in school. Thanks to a large international collaboration, the EuCARE project is trying to provide advances in a wide variety of SARS-COV-2 variants related topics.
The symposium on Covid-19 and post-Covid conditions in 2024: data from the EuCARE project will be held on June 20th from 15:25 to 17:30.
A new phase of the KRG-HIS Project
May 2024
A very important milestone for the KRG-HIS Project achieved in Kurdistan with the signature of the Memorandum of Understanding between University of Tor Vergata and the Ministry of Health of Kurdistan.
The new phase of the KRG-HIS Project started with the visit of Tor Vergata University and EuResist representatives to the Kurdish Health Directorates with a two years plan for the complete integration of the system in the Health administration of the Region.
AVITHRAPID project kickoff!
13-14 February 2024
On 13 and 14 February in Rome, at the National Institute of Infectious Diseases, it was held the kickoff meeting of the AVITHRAPID project devoted to search and validation of broad spectrum "Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases".
EuResist is proudly partner of the project, in charge of the data management of the Project's clinical trials.
New EuCARE publication in the Lancet Regional Health- Europe
06 February 2024
The reduced mortality from COVID-19 is not necessarily due to lower severity of latest variants, such as Omicron and its sub-variants.
Rather, the reduced mortality seems to be due to other factors, such as immunity from previous vaccinations and previous infections.
This is among the outcomes of the study "Twenty-Eight-Day In-Hospital Mortality During the Wild-type, Alpha, Delta, and Omicron SARS-CoV-2 Waves: A Multinational Cohort Study in the EuCARE Project" published in the latest issue of The Lancet Regional Health Europe.
The study, which analyses data from 38,585 adult patients from the EuCARE Hospitalised cohort, comprising 10 centres across Europe, Kenya and Mexico, also highlighted that age is an important effect measure modifier regarding the association between variant and in-hospital mortality, highlighting the importance of performing age-stratified analyses, also by variant.
From the left: A. Sönnerborg (KI), P. Naucler (KI), P. Herdberg (1st author),
A. Cozzi-Lepri (UCL)
They talk about us
An algorithm for Africa
EuCARE kick-off project on TV
EuCARE per capire l'impatto delle varianti di SARS-CoV-2
29 July 2024
The published guide accomplished to deliver a very important and impactful resume about the EuCARE project highlighting the main research focuses and its results. Furthermore, the article described the project collaborations established and the partners involved.
La didattica a distanza migliora voti e fiducia negli studenti? Gli studi scientifici dicono altro.
8 July 2024
EuCARE article published online on Il fatto quotidiano about distance learning and the impact on students grades and confidence.
EuCARE studia l'impatto del Covid-19: quali sono le migliori azioni da intraprendere in situazioni di emergenza.
20 December 2023
EuCARE and the issue of preparedness on Il Sole 24 Ore, Italy's leading business daily newspaper.
Il Covid ha lasciato rabbia negli studenti
13 May 2023
Article published in regional newspaper on the preliminary results of the EuCAREschool study presented during the "WeCARE for Schools" event
Covid, al via un progetto per analizzare l’effettivo contagio nelle scuole
2 June 2022
Da settembre lo studio di EuCARE. Sotto la lente anche l'impatto psicologico delle restrizioni e l'eventuale perdita di apprendimento a esse associata.
EuCARE: partito lo studio internazionale sul ruolo della scuola durante la pandemia
19 June 2022
Il Metodo Lolli già applicato in 3 istituti a Lodi e Lecce
Covid, nelle scuole italiane arriva il progetto europeo ‘Eucare’
1 June 2022
Si tratta di uno studio scientifico internazionale per adottare le migliori pratiche per tutelare tutti gli studenti in queste nuove fasi della pandemia
Audible by Radio Radicale:
9 November 2021
Audible by Rai GR Parlamento
15 May 2022
Coordinated by Euresist Network, 25 primary universities, hospitals and ICT research centres are collaborating to provide robust, data driven evidence to deal with SARS-CoV-2 variants and COVID-19 epidemics.
How do SARS-COV-2 variants, coupled with other factors, influence the clinical course of COVID-19? Is there any vaccine or test escape related to variants? Do variants influence, and how, the spread in the school setting? Can we define a better testing and containment strategy in the school setting? What is the impact of containment measures, including schools closure, on pupils and teachers?
With the support of strong immuno-virological and artificial intelligence components, the study will take advantage of large hospital patients, vaccinated healthcare workers and schools’ cohorts in Europe, Kenya, Mexico, Russia and Vietnam to find an answer to urgent issues related to science and society....
CARE
CARE (Common Action against HIV/TB/HCV across the Regions of Europe) aims at analysing and addressing the human immunodeficiency virus (HIV), tuberculosis (TB) and hepatitis C (HCV) epidemics across Europe and Russia, by establishing new networks and consolidating previous cooperative actions between the European Union and the Russian Federation.
MDR
The MDR project (HIV multidrug resistance pathways in the EuResist Integrated DataBase) aims at estimating the prevalence and trend over time of MDR (multidrug resistance) in HIV patients, using descriptive statistics, retaining high value because of the large sample size and wide representativeness of the EIDB.
The INTEGRATE project aims at building and maintaining a large, curated collection of virological and clinical data to increase scientific knowledge on resistance to integrase strand transfer inhibitors (InSTI) and on the most appropriate use of this class of antiretroviral agents.
Ciao Andrea.
On Feb 4th 2019, our great friend and EuResister Andrea De Luca lost his life in a horrible car accident, at the age of 55.
One year has passed and still we miss him with incredulity and sorrow.
Among many other projects, Andrea joined EuResist as a key leader soon after its launch, devoting his energy, commitment and capability to the success of the Network. He was an extra lively, smart, passionate, and positive person, always ready to help and take new tasks.
His loss is a huge loss for us, for his patients, for his beloved ones, for the international research community.
Ciao Andrea, we'll always miss you.